Pfizer filed an antitrust lawsuit on Monday accusing Danish drugmaker Novo Nordisk of structuring its $9 billion bid for biotech Metsera to stall, not close, the deal, a tactic it said is designed to suppress competition in obesity drugs.

Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what I see in store for PFE and MTSR stock.

Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's patent cliff strategy appears to be working so far.

The Danish and American companies have sensed the potential of the biotech company, which could help them recover. Pfizer is now seeking judicial intervention and filing a civil lawsuit against Novo Nordisk.

The start-up is making antivirals and cancer drugs for Big Pharma—and working to treat reproductive problems on its own

According to a new BioPharma Dive analysis, corporate-related funds such as Novo Holdings, Eli Lilly and Sanofi Ventures have been among the most active investors in biotech startups this year.

MONTREAL, Nov. 6, 2025 /CNW/ - The Canadian Paralympic Committee (CPC) and Pfizer Canada have extended their partnership, with 2026 marking 30 years of working together to support and promote Paralympic sport.

Morning Brief host Julie Hyman outlines three stories investors are watching on Tuesday, Nov. 4. US stock futures (ES=F, NQ=F, YM=F) are under pressure as Palantir (PLTR) stock weighs on the broader market after the company reported earnings results.